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Abstract
Background: Metastatic melanoma has a high mortality rate and suboptimal therapeutic options.
Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid × receptor selective
agonist, and thiazolidinediones (TZD), PPARγ selective ligands, as novel treatments.
Results: Mouse xenograft models with human melanoma cell lines [A375(DRO) or M14(5–16)]
were treated for 4 weeks with daily vehicle, RXR agonist (rexinoid, LGD1069, 30 mg/kg/d), PPARγ
agonist (TZD, rosiglitazone, 10 mg/kg/d) or combination. A375(DRO) tumor growth was
significantly inhibited by either ligand alone and the combination had an additive effect. M14(5–16)
tumors only responded to LGD1069 100 mg/kg/day. A375(DRO) sublines resistant to rexinoid,
TZD and combination were generated and all three sublines had reduced PPARγ expression but
preserved RXR expression. shRNA knockdown of PPARγ or RXRγ attenuated the rexinoid, TZD
and combination ligand-mediated decreased proliferation in A375(DRO) cells. Rexinoid
(LGD1069) and retinoid (TTNPB) treatment of M14(5–16) cells resulted in decreased proliferation
that was additive with combination of both rexinoid and retinoid. shRNA knockdown of RXRγ
resulted in a decreased response to either ligand.
Conclusion: A375 (DRO) melanoma cell growth is inhibited by rexinoid and TZD treatment, and
this response is dependent on RXR and PPARγ receptor expression. M14 (5–16) melanoma cell
growth is inhibited by rexinoid and retinoid treatment, and this response is dependent on RXR
expression. These findings may help guide molecular-based treatment strategies in melanoma and
provide insight for mechanisms of resistance to nuclear receptor targeted therapies in certain
cancers.
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Background
Melanoma represents a significant public health problem
with a rising incidence over the last 3 decades[1]. More
than 7700 patients will die annually of this disease,
almost all with metastases [2]. Much of the research and
current treatment for advanced stage malignant
melanoma has utilized immunomodulating strategies
including the use of interferon-α, other cytokines and vac-
cines[3].
Our group has long been interested in the study of nuclear
hormone receptor targeted therapy for the treatment of
poorly differentiated cancer with a primary focus on the
retinoid receptors and peroxisome-proliferator activated
receptor gamma (PPARγ) as novel therapeutic targets.
Retinoid receptors can be divided into two broad catego-
ries of retinoic acid receptors (RAR) and retinoid × recep-
tors (RXR), each with three separate isotypes encoded by
6 different genes (RAR α, β, γ and RXR α, β, γ)[4,5]. We
have evaluated the utility of both RAR and RXR specific
ligands (rexinoids) as well as PPARγ ligands to decrease
cancer cell proliferation, increase apoptosis and inhibit
tumor growth with in vitro and in vivo experiments [6-8].
There is data to suggest that nuclear hormone receptors
may be important and relevant targets in melanoma.
RXRs have been described as "auxiliary" receptors that
enhance DNA binding of RAR and other nuclear hormone
receptors, including PPARγ [9]. More recent studies, how-
ever, showed that selective activation of RXR could lead to
transcriptional activation, apoptosis and redifferentiation
of embryonal carcinoma cells, and that the effects of RAR
and RXR selective ligands in combination were additive
[10]. LGD1069, a rexinoid known as bexarotene, is
approved for use in cutaneous T-cell lymphoma and has
been studied as adjuvant therapy for non-small cell lung
cancer [11,12].
PPARγ receptors have been demonstrated in primary
human tissues as in a study by Mossner et al. that showed
positive immunostaining for PPARγ in 14/14 nevi, 10/11
primary melanoma lesions and 6/8 melanoma metas-
tases[13]. Placha and colleagues performed in vitro prolif-
eration analyses on two PPARγ expressing melanoma
cells: WM35, a primary melanoma lesion and A375.
Using an older generation TZD, ciglitazone (5 μM), there
was a significant decrease in cell proliferation at 48 hours
[14].
Recently, we have reported that our earlier data was
largely based upon cell lines that have been misidentified.
Two of our rexinoid responsive cell lines were DRO90-1
and BHP 5–16, likely sub-lines of the melanoma cell lines
A375 and M14 respectively [15]. Both cell lines express
RXRγ, which is associated with response to rexinoid ther-
apy in vitro for BHP 5–16 and both in vitro and in vivo in
DRO90-1[7,8]. Additionally, RARβ expression is associ-
ated with treatment response using the RAR selective lig-
and TTNPB in vitro in BHP 5–16 only[6]. DRO90-1 is
unique in that it also expresses PPARγ, which is activated
by the thiazolidinedione (TZD) class of drugs (PPARγ ago-
nists). We have observed that rexinoid treatment of
DRO90-1 yields a greater decrease in proliferation as com-
pared to BHP 5–16 (RXRγ+, PPARγ-) with a component of
this effect due to a decrease in S phase and an increase in
G2/M phase of the cell cycle[6]. Additionally, combina-
tion therapy with rexinoid and TZD of DRO90-1 in vitro
yields a synergistic antiproliferative and pro-apoptotic
response [7]. DRO90-1 also has a dose dependent
decrease in tumor growth to rexinoid in vivo [8].
In this report, we expand upon our in vivo nude mouse
model that analyzes the response of BHP 5–16 and
DRO90-1 xenograft tumors to LGD1069 and rosiglita-
zone (ROSI), a TZD. Additionally, we examine the func-
tional importance of RXRγ and PPARγ receptors in these
cell lines by a unique model of resistance to rexinoid and
TZD therapies in DRO90-1, as well as nuclear hormone
receptor inhibition by short hairpin RNA (shRNA)
directed at PPARγ (shPPARγ) in DRO90-1 and RXRγ
(shRXRγ) in both DRO90-1 and BHP 5–16[16].
Results
In vivo A375(DRO) tumor growth is synergistically 
inhibited by combination treatment with rexinoid and TZD
We have previously shown that A375(DRO) xenograft
tumor growth is inhibited by 30 and 100 mg/kg/day of
LGD1069 in a dose dependent manner [8]. Additionally,
a combination of low-dose RXR and PPARγ agonists sig-
nificantly inhibited growth of A375(DRO) cells in vitro
[7]. Therefore, nude mice harboring established
A375(DRO) tumors (100–200 mm3) were treated with
LGD1069 30 mg/kg/day (as previously described), ROSI
10 mg/kg/day or a combination of the two drugs.
LGD1069 and ROSI treatments alone each had a modest
effect on tumor growth (figs. 1a, 52% and 36% smaller
than control respectively). Combination LGD1069 and
ROSI inhibited tumor growth by 73% compared with
controls. All tumor sizes at the end of the treatment were
significantly smaller that untreated mice (p = 0.002, 1-way
ANOVA Kruskal-Wallis method).
No metastases were observed grossly after an examination
of lung and liver parenchyma in the control or treatment
groups. Tumors in the ROSI or LGD1069 single therapy
groups showed 57.5 ± 12.8% and 40 ± 12.2% necrosis
respectively while the control tumors, though much
larger, only showed 28.8 ± 14.6% necrosis. The control
and LGD1069 treated tumors showed marked vacuoliza-Molecular Cancer 2009, 8:16 http://www.molecular-cancer.com/content/8/1/16
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tion in the viable tissue. Interestingly, the combination
therapy group had the lowest amount of necrosis (21.3 +
15.3%) (p < 0.001 for all groups, 1-way ANOVA).
An in vitro model of resistance to LGD1069 and TZD 
decreases A375(DRO) PPARγ expression
We have previously shown that 10 nM of LGD1069, PIO
or the combination has no antiproliferative effects, but
100 nM and 1 μM of each drug alone and in combination
inhibited cell growth by 90–98% compared to control [7].
Both PIO and ROSI have shown a similar inhibition of
proliferation indicating a TZD class effect in this model
(data not shown).
We generated drug resistant sub-lines of A375(DRO) by
treating these cells in 10 nM of either ligand alone or in
combination and increasing the concentration of drug as
described in the methods until the cells had similar
growth rates as cells grown in volume equivalent vehicle
for the same period of time (~14 weeks). These cell lines
were renamed based on the drug resistance generated
(DMSO R – control cells, LGD1069 R – rexinoid resist-
1a: In vivo tumor response of A375(DRO) xenograft tumors Figure 1
1a: In vivo tumor response of A375(DRO) xenograft tumors. 5 × 106 A375(DRO) cells were injected s.c. and tumors 
were allowed to grow for 3.5 wk after tumor establishment (~100 mm3). After estblishment, treatment conditions were (A) 
control, (B) 30 mg/kg/d LGD1069, and (C) 10 mg/kg/d ROSI and (D) combination of 30 mg/kg/day LGD1069 and 10 mg/kg/day 
ROSI. Tumors were measured twice per week. Points, mean tumor volume/group; bars, SEM. One Way ANOVA – Kruskal-
Wallis test was used to assess the significance of the difference of tumor sizes at the end of the experiment (*P = 0.002). 1b: 
representative control tumor showing approximately 20% necrosis (*). Marked cellular vacuolization is seen in the non-
necrotic tissue. Hematoxyline and Eosin staining 2× magnification. 1c: An enlarged picture from the control tumor showing the 
junction of the necrotic (*) and the viable, yet markedly vacuolated melanoma cells. Hematoxyline and Eosin staining. 40× mag-
nification. 1d: A representative Rosi treated tumor with > 70% necrosis (edged by arrows) of the total tissue volume with a 
small rim of viable tumor. Hematoxyline and Eosin staining 2× magnification.
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ance, TZD R – pioglitazone resistance and LG/TZD R –
resistance to combination rexinoid and TZD).
To confirm drug resistance, we performed proliferation
assays with 1 μM of each ligand alone or in combination
(10 × higher drug concentration than the final growing
conditions of 100 nM). We first confirmed that the con-
trol A375(DRO) cells that were grown in volume equiva-
lent vehicle had a similar response to early passage
A375(DRO) cells exposed to volume equivalent vehicle
(DMSO) (data not shown). Figure 2 shows that LGD1069
R cells were resistant to growth inhibition by 1 μM
LGD1069 as expected, but surprisingly also lost the
growth inhibitory effect of TZD, despite no exposure to
TZD. These LGD1069 R cells also had significant attenua-
tion of growth inhibition by LGD/TZD combination. TZD
R cells attenuated growth inhibition by LGD and TZD
alone compared to DMSO R cells. LGD/TZD R cells were
completely resistant to growth inhibition by all condi-
tions as was expected. The attenuation of the treatment
effect to all treatment conditions compared to the control
cell line (DMSO R) was significant (p < 0.03) except for
the TZD R subline treated with combination LGD/TZD
(fig 2).
Proliferation of resistant A375(DRO) cells: "resistant" cells were grown in 2% fetal bovine serum RPMI in the presence of 1  μmol/L of LGD1069, TZD or the combination for 9 days Figure 2
Proliferation of resistant A375(DRO) cells: "resistant" cells were grown in 2% fetal bovine serum RPMI in the 
presence of 1 μmol/L of LGD1069, TZD or the combination for 9 days. Cell growth was analyzed using a nonradioac-
tive cell proliferation assay. Proliferation was compared to that of cells grown in volume equivalent vehicle (DMSO – repre-
sented by the line) and resistant sublines were compared to the DMSO R control to assess the attenuation of response to 
receptor specific ligands. Proliferation was statistically significantly attenuated compared to the control DMSO R in all resistant 
cell lines and condition save for combination therapy in TZD R (p < 0.03). Columns, mean; bars, SEM.
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We next examined nuclear protein levels of RXRα, RXRγ
and PPARγ in each of the drug resistant sub-lines of
A375(DRO) (fig 3a). Interestingly, RXRα and RXRγ pro-
tein levels were unaffected, but PPARγ was lower in all 3
sublines, with the LGD/TZD R cells having 71% less
PPARγ receptor relative to DMSO R (fig 3b).
shRNA for PPARγ and RXRγ in A375(DRO) attenuates 
both LGD1069 and ROSI treatment response to both 
ligands
In order to directly determine the roles and functional
activity of PPARγ and RXRγ in treatment response to TZD
and rexinoid in A375(DRO) cells, we performed shRNA
knock-down of these receptors.
Western blot analysis demonstrated loss of PPARγ protein
in two distinct shPPARγ clones compared with scrambled
shRNA control (SCR) or non-infected cells (fig 4a). We
confirmed decreased mRNA by qRT-PCR to verify the loss
of protein expression was occurring at the mRNA level
(data not show). shPPARγ had no effect on RXRα, RXRγ or
RARβ protein levels.
To assess the functional importance of PPARγ expression,
we performed the proliferation assay as described (mate-
rials and methods) after 9 days of treatment using the SCR
as a control for the lentiviral infection and two represent-
ative shPPARγ clones (1674 and 1673). A375(DRO) SCR
control cells had a robust growth inhibitory response to
ligand treatment that was similar to non-infected
A375(DRO) cells. As expected, shPPARγ cells lacking
PPARγ protein were no longer growth inhibited by TZD
(fig 4b). Interestingly, growth inhibition by LGD1069 was
significantly attenuated in these cells lacking PPARγ but
with intact RXRα and RXRγ protein. These genetic experi-
ments confirm our observations using the pharmacologic
resistance model (fig 2 and 3). Growth inhibition by com-
bination LGD/TZD was also attenuated in these cells lack-
ing PPARγ.
We next performed the converse experiment in
A375(DRO) by using shRXRγ inhibition to knock down
RXRγ protein. Infection with the shRXRγ clone 1643
resulted in loss of RXRγ protein expression in (fig. 5a). Fig-
ure 5b shows that knock-down of RXRγ resulted in signif-
icant attenuation, but not complete loss of inhibition of
proliferation for each of the three ligand treatment condi-
tions, indicating that RXRγ or some level of total RXR is
necessary for the full suppressive effect of rexinoid, TZD
and combination on A375(DRO) cell growth. shRXRγ
infection appears to have partially decreased RXRα pro-
tein expression as well (likely via an indirect mechanism
since shRXRγ are highly specific for RXRγ) which may con-
tribute to the diminished LGD1069 effect.
shRXRγ in M14(BHP 5–16) decreases the treatment effect 
of both LGD1069 and TTNPB monotherapy
We have previously demonstrated that in vitro, M14(5–
16) does not respond to TZD and the antiproliferative
effect to combination therapy with rexinoid and TZD is
driven by the rexinoid effect[7]. These observations were
confirmed in the in vivo xenograft where ROSI alone had
no effect, nor did combination therapy with the lower
dose of LGD1069 at 30 mg/kg/day combined with ROSI
10 mg/kg/day (data not shown). In the LGD1069 100
mg/kg/day treatment arm, there was a modest but signifi-
cant effect on M14(5–16) tumor growth. Control tumors
measured 1085 ± 68 mm3 and treated tumors measured
866 ± 70 mm3 (p = 0.04).
We have previously shown that the M14(5–16) responds
to both RXR and RAR agonists with approximately 40–
60% decreased proliferation compared to vehicle treated
cells [6]. Based on our observations of the robust response
Western blot of nuclear hormone receptors in A375(DRO)  resistant cell lines Figure 3
Western blot of nuclear hormone receptors in 
A375(DRO) resistant cell lines. 3a: 60 μg of nuclear pro-
tein extract from the resistant A375(DRO) sublines was size-
separated on a 10% SDS-PAGE gel and transferred to nitro-
cellulose. The blot was blocked with 10% nonfat milk and 
incubated with RXRγ (MS-1343-P NeoMarkers) and RXRα 
(sc D-20) antibodies at a concentration of 1:500 and PPARγ 
(H-100) rabbit polyclonal ab (sc-7196, Santa Cruz Biotech-
nology, Santa Cruz, CA) at 1:500. Secondary antibodies were 
anti-rabbit IgG conjugated to horse-radish peroxidase at a 
1:5000 dilution for RXRs and 1:1000 for PPARγ (GE Health-
care UK). β-Actin was measured as a loading control. 3b: 
PPARγ receptor to β-Actin ratio was calculated using an 
Alpha Innotech alpha imager.
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of RXR:PPARγ heterodimer activation in A375(DRO), we
evaluated if combination therapy with LGD1069 and
TTNPB (RAR selective ligand) would result in a similar
additive or synergistic antiproliferative response.
We treated M14(5–16) with 1 μM LGD1069, TTNPB or
the combination (500 nM of each) for 6 days. There was
a modest but significant decrease in proliferation of 24%,
22% and 38% respectively compared to control condi-
tions (p = 0.001). Additionally, the combination provided
an additive response that was significant (16% reduction
beyond either ligand alone compared to control, p = 0.02)
(fig. 6a).
We then tested if shRXRγ would attenuate the antiprolifer-
ative response of LGD1069, TTNPB and the combination.
We used the same shRXRγ clone (1643) that provided the
greatest protein inhibition in the A375(DRO) cell line.
Knock-down of RXRγ resulted in a significant attenuation
of the treatment response for each treatment condition
compared with SCR control cells (p ≤ 0.02) (fig. 6a).
Western blot analysis demonstrated significantly
decreased RXRγ protein in M14(5–16) after infection with
the 1643 shRXRγ clone. RXRα protein expression was
maintained at a similar level to un-infected cells. How-
ever, RARβ expression was also decreased in the shRXRγ
infected cells compared to the non-infected M14(5–16)
and control SCR cells (fig. 6b).
Discussion
In this report, we have demonstrated for the first time that
the combination of a rexinoid and TZD effectively inhibits
growth of differentiated melanoma expressing PPARγ and
RXRγ using an in vivo model. Additionally, we have shown
through a model of induced cell line resistance and
shRNA mediated nuclear hormone receptor knockdown
the requirement that both RXR and PPARγ are required for
Western blot of nuclear hormone receptors and proliferation in A375(DRO) cells with shPPARγ infection Figure 4
Western blot of nuclear hormone receptors and proliferation in A375(DRO) cells with shPPARγ infection. A. – 
60 μg of nuclear protein extract from A375(DRO), the SCR shRNA infected control cell and two clones of shPPARγ infec-
tions. Proteins were size-separated on a 10% SDS-PAGE gel and transferred to nitrocellulose. The blot was blocked with 10% 
nonfat milk and incubated with RXRγ, RXRα and RARβ primary antibodies and then secondary antibody with anti-rabbit IgG 
conjugated to horse-radish peroxidase as previously described. β-actin was measured as a loading control. B. – A375(DRO), 
the SCR infected and two shPPARγ infected sublines were grown in 2% fetal bovine serum RPMI in the presence of 1 umol/L of 
LGD1069, TZD or the combination for 9 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Prolif-
eration was compared to that of cells grown in volume equivalent vehicle (DMSO – represented by the line). Proliferation of 
the SCR infected A375(DRO) was compared to the native cell line to confirm a similar response and then the shPPARγ cell 
lines were compared to the SCR condition for an assessment of decreased proliferation. Proliferation was statistically signifi-
cantly attenuated compared to the A375(DRO) SCR subline in all treatment conditions (p < 0.001). Columns, mean; bars, SEM.Molecular Cancer 2009, 8:16 http://www.molecular-cancer.com/content/8/1/16
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maximal effect of either ligand. Finally, we have demon-
strated that a combination of a selective rexinoid and
retinoid agonists has an additive effect on growth inhibi-
tion of a melanoma cell line expressing RARβ and RXRγ.
We have previously reported the efficacy of a combination
of rexinoid and TZD to inhibit cell proliferation and pro-
mote apoptosis in A375(DRO)[7]. Additionally, we have
demonstrated that LGD1069 inhibits A375(DRO) tumor
growth in a nude mouse model[8]. We originally reported
DRO as an anaplastic thyroid carcinoma, but we have
recently shown by short tandem repeat (STR) analysis
DRO matches the profile of A375, a poorly differentiated
amelanotic melanoma that was established almost 20
years before the reported establishment of DRO [15].
Studies of the use of retinoids for melanoma therapy are
limited. Niu and colleagues examined the in vitro effects of
non-selective retinoids, an RXR selective agonist (metho-
prene acid) and the RAR selective agonist TTNPB on A375
cells [17]. They found that TTNPB and non-selective retin-
oids led to a greater antiproliferative and apoptotic
response than the RXR selective agonist. This directly con-
tradicts our data in that we have shown that RXR selective
agonists leads to decreased cell growth and TTNPB does
not in our A375(DRO) cells [6]. There are important dif-
ferences in the two studies including different culture con-
ditions, our use of a different RXR agonist and a no
presentation of receptor expression by Niu et al. It is pos-
sible that genetic drift in culture has led to alterations in
nuclear hormone receptor expression. Alternatively, the
Western blot of nuclear hormone receptors and proliferation in A375(DRO) cells with shRXRg infection Figure 5
Western blot of nuclear hormone receptors and proliferation in A375(DRO) cells with shRXRg infection. A. – 
60 μg of nuclear protein extract from A375(DRO), the SCR shRNA infected control cell and a clone of shRXRγ infected cells 
were size-separated on a 10% SDS-PAGE gel and transferred to nitrocellulose. The blot was blocked with 10% nonfat milk and 
incubated with RXRγ, RXRα and PPARγ primary antibodies and then secondary antibody with anti-rabbit IgG conjugated to 
horse-radish peroxidase as previously described. β-actin was measured as a loading control. B. – A375(DRO), the SCR infected 
and the shRXRγ infected sublines were grown in 2% fetal bovine serum RPMI in the presence of 1 umol/L of LGD1069, TZD 
or the combination for 9 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Proliferation was com-
pared to that of cells grown in volume equivalent vehicle (DMSO – represented by the line). Proliferation of the SCR infected 
A375(DRO) was compared to the native cell line to confirm a similar response and then the shRXRγ infected cell line was 
compared to the SCR condition for an assessment of attenuation of decreased proliferation. Proliferation was statistically sig-
nificantly attenuated compared to the A375(DRO) SCR subline in all treatment conditions (p < 0.05). Columns, mean; bars, 
SEM.
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greatest response shown by Niu et al. was with 10 μM
retinoid, which may be a concentration that exerts effects
via non-receptor mediated mechanisms. Alternatively, in
another melanoma cell line, S91, RXR selective ligands
had a greater antiproliferative effect than RAR ligands[18].
The BHP 5–16 subline of the melanoma M14 responds to
both RXR and RAR selective ligands (LGD1069 and
TTNPB respectively) with decreased proliferation[6]. We
assessed if the combination of these two ligands would
lead to an additive or synergistic response via dual activa-
tion RXR and RAR receptors. Treatment with LGD1069
and TTNPB in combination at 1/2 the dose of each ligand
used alone did lead to a modest and statistically signifi-
cant decrease in proliferation, indicating at least an addi-
tive effect. Knockdown of RXRγ blunted the effect of both
LGD1069 and TTNPB alone. The LGD1069 attenuation is
easily explained by the decreased RXR expression. Despite
the shRXRγ sequence being specific for RXRγ, we found
lower protein levels of RARβ. The reason for this is
unclear, but could possibly be explained by the require-
ment of functional RXR protein to be present for recruit-
ment of RARβ from the cytoplasm to the nucleus for DNA
binding (our proteins for western blot were enriched for
nuclear extracts). Ikeda and colleagues demonstrated no
detectable RARβ2 protein in S91 melanoma cells until
treatment with an RXR selective agonist by dimethyl sul-
fate-based genomic footprinting[19]. Alternatively, intact
RXR signaling may be required for RAR protein stability
by an unknown mechanism.
There has been one clinical trial with rexinoid therapy and
melanoma, a phase II study using bexarotene in 19
patients with metastatic melanoma [20]. This was a non-
Proliferation response of M14(5–16) with shRXRg infection and western blot of these cells Figure 6
Proliferation response of M14(5–16) with shRXRg infection and western blot of these cells. A – M14(5–16), the 
SCR infected and the shRXRγ infected subline was grown in 2% fetal bovine serum RPMI in the presence of 1 μmol/L of 
LGD1069, TTNPB or the combination for 6 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Pro-
liferation was compared to that of cells grown in volume equivalent vehicle (DMSO – represented by the line). Each treatment 
condition led to a significant decrease in proliferation compared to control (p < 0.001). The combination of LGD/TTNPB had a 
statistically significantly greater decrease in proliferation than each alone (*p = 0.02). Proliferation of the SCR infected M14(5–
16) was compared to the native cell line to confirm a similar response and then the shRXRγ infected cell line was compared to 
the SCR condition for an assessment of attenuation of decreased proliferation. Proliferation was significantly attenuated com-
pared to the M14(5–16) SCR subline monotherapy conditions (p ≤ 0.02). Columns, mean; bars, SEM. B – 60 μg of nuclear pro-
tein extract from M14(5–16), the SCR shRNA infected control cell and a clone of shRXRg infected cells were size-separated 
on a 10% SDS-PAGE gel and transferred to nitrocellulose. The blot was blocked with 10% nonfat milk and incubated with 
RXRγ and RXRα primary antibodies and then secondary antibody with anti-rabbit IgG conjugated to horse-radish peroxidase 
as previously described. RXRγ is represented as a doublet because of cross-reaction of the RXRγ1 and RXRγ2 isoforms. PARP 
was measured as a loading control.
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controlled study that evaluated the size and number of
lesions by palpation or imaging after initiation with a
maximum recommended dose of bexarotene. The best
response seen was stable disease in one patient. Stable dis-
ease for malignant melanoma could be considered a sig-
nificantly beneficial therapeutic outcome, although it was
observed in only one patient and there was no untreated
control group. Most importantly, there was no correlation
of response (or lack of response) to RXR presence in either
primary or metastatic lesions. Our data shows that RXRγ
predicts response to LGD1069, though we cannot be cer-
tain if this is specific to RXRγ or total RXR protein levels.
A recent study using tissue microarrays gives an indication
of the potential negative outcome in the above described
trial[21]. Chakravarti et al. showed a significant decrease
in RARβ, RARγ and RXRα expression in melanoma lesions
compared to nevi. Additionally, of lesions with satellito-
sis, there was decreased RXRγ expression. The authors
went on to show a decrease in overall survival in patients
whose tumors had lower cytoplasmic staining for RARγ
and RXRα. These data suggest that as melanoma becomes
more aggressive and dedifferentiated, there is an associ-
ated loss of retinoid nuclear hormone receptor expression.
Perhaps, earlier adjuvant therapy with retinoids in high
risk patients prior to a loss of receptor expression would
provide benefit.
There is a larger body of research evaluating the role of
PPARγ activation in melanoma. Nunez et al. evaluated the
role of TZDs in an amino acid deprivation experiment and
showed that TZD could promote apoptosis in A375 at 48
hours, albeit with very high doses of ciglitazone (50
μM)[22]. We have shown a significant increase in apopto-
sis in A375(DRO) at 6 days with only 1 μM PIO[7].
Weng et al. demonstrated that with modified TZD mole-
cules that no longer bound and activated PPARγ, they
could still induce antiproliferative and apoptotic effects
on a variety of unrelated cancer cells[23] suggesting that
TZDs had anticancer effects unrelated to PPARγ activation.
However, these studies utilized high concentrations of
compound (10 μM) to see any effect. In contrast, Aiello
and colleagues demonstrated a complete blunting of the
antiproliferative effect of TZDs on a variety of responsive
anaplastic thyroid cancer (ATC) cells when PPARγ expres-
sion was diminished by siRNA and TZD concentrations of
10 μM were used for 4 days. A significant component of
growth inhibition of cancer cells upon agonist activation
of PPARγ is due to up-regulation of the cell cycle inhibitor
p21WAF1/CIP1 as demonstrated by Copland et al[24]. Using
a PPARγ antagonist (GW9662) and siRNA of PPARγ in
poorly differentiated cancer cells, the authors showed a
blunting of promoter activity, antiproliferative activity
and p21WAF1/CIP1 up-regulation by PPARγ activation.
Only one other study has evaluated combination therapy
with a rexinoid and TZD of a moderately differentiated
carcinoma xenograft model. Cesario and colleagues [25]
used a combination of 50 mg/kg/day LGD1069 and 15
mg/kg/day rosiglitazone and showed decreased tumor
growth compared to either ligand alone. In our nude
mouse model, we have previously shown that 100 mg/kg/
day of LGD1069 markedly decreases A375(DRO) tumor
growth and that this is associated with increased necro-
sis[8]. Using the same study design, the addition of 10
mg/kg/day of ROSI allows a similar tumor response with
only 30 mg/kg/day of LGD1069. The in vivo effect of com-
bination treatment seems to act primarily via decreasing
growth as opposed to causing cell death as these tumors
were the smallest and displayed the least amount of
necrosis on a careful histological examination. These find-
ings translate our previously published in vitro findings
with A375(DRO) to an in vivo model[7].
The combination of retinoids and TZDs has been studied
in two other models of cancer. Yamazaki [26]et al. trans-
fected mutant (to mimic the unphosphorylated, active
form) RXRα into Caco2 cells (that have endogenous
expression of PPARγ) and then treated with relatively high
doses of 9-cis RA (5 μM), which has both RXR and RAR
agonist properties, and ciglitazone (10 μM). They found a
synergistic decrease in viable cell counting and increase in
apoptotic markers. Similarly, Hashimoto and colleagues
[27] used a combination of 9-cis RA and troglitazone in
the same concentrations on the KYSE series of esophageal
carcinoma cell lines that all express high levels of RXRα
and variable (though present) levels of PPARγ. They
found a synergistic decrease in cell number, increased
PARP cleavage and increased cell number in sub-G1 cell
cycle phase with combination treatment.
Our study is unique in that we have evaluated the func-
tional contribution of nuclear hormone receptor integrity
to rexinoid and TZD activation of RXR and PPARγ recep-
tors. We have demonstrated this functional partnership in
A375(DRO) (likely a heterodimer) by two separate meth-
ods. The first strategy was a model of forced resistance to
rexinoid and TZD therapies in vitro. The ability to create
resistant cell lines to previously effective therapies has
been demonstrated in previous studies including forced
resistance to gemcitabine and paclitaxel in NSCLC
[28,29]. These studies utilized a pulse therapy approach to
generate drug resistance, whereas we have performed an
increasing dose titration of LGD1069 and TZD. These
experiments gave us insight into the relative importance
of PPARγ in this model as RXRγ and RXRα levels were
maintained, while PPARγ levels were decreased, even in
the setting of resistance to LGD1069. This observation
was supported by a direct shRNA experiment where
knockdown of PPARγ markedly attenuated not only theMolecular Cancer 2009, 8:16 http://www.molecular-cancer.com/content/8/1/16
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antiproliferative response of TZD therapy, but also
LGD1069 treatment. In the converse experiment, though
affected, the response to TZD was not nearly as affected by
RXRγ knockdown, though LGD1069 response was
blunted. This suggests that in the A375(DRO) cell model,
PPARγ plays a more prominent role in mediating the tran-
scriptional response to either an RXR agonist, PPARγ ago-
nist or the combination. The implication for clinical
analysis of resistant tumors to nuclear hormone targeted
therapies is that loss of expression of an "off-target" recep-
tor may generate resistance if it is in a heterodimeric part-
nership with the "on-target" nuclear hormone receptor.
Conversely, co-expression of RXR and PPARγ may suggest
a higher potential response to either bexarotene or TZD
alone, or the combination.
Conclusion
In conclusion, combination therapy of a rexinoid with a
retinoid or other nuclear hormone receptor, such as
PPARγ, has the potential to decrease tumor growth in
poorly differentiated cancers with the appropriate protein
targets. Loss (or loss of function) of a nuclear hormone
receptor that would otherwise act as a heterodimer part-
ner may explain why targeted therapies to nuclear hor-
mone receptors have limited or no efficacy. In general, as
tumors become poorly differentiated and more wide-
spread, they tend to lose expression of retinoid recep-
tors[21,30,31]. Thus, earlier targeted therapy in aggressive
variants of cancers may provide benefit by preventing
aggressive biological behavior and dissemination.
Methods
Chemicals
All cancer cells were grown in RPMI 1640 media (Invitro-
gen Corporation, Carlsbad, CA) supplemented with 2%
fetal bovine serum (FBS) (Hyclone, Logan, UT) and 0.2%
Penicillin/Streptomycin. LGD1069 was provided by Lig-
and Pharmaceuticals (San Diego, CA). We utilized two
TZDs; rosigllitazone (ROSI) was provided by GlaxoSmith-
Kline (Barnard Castle Durham, UK) and pioglitazone
(PIO) was provided by Takeda Pharmaceuticals (Osaka,
Japan).
Cell Lines
DRO90-1 was provided by Dr. G.J. Juillard (UCLA). BHP
5–16 was provided by Dr. Jerome Hershman (UCLA).
These cancers have been shown to be misidentified as fol-
lows: DRO90-1 matches the STR profile of A375
(melanoma), BHP 5–16 matches M14 (melanoma) [15].
Thus, by our own convention, these cell lines will be
named as follows: A375(DRO) and M14(5–16). This
name identifies the parent cell line, but distinguishes
them as unique sub-lines that may have differential
responses to similar treatments for A375 or M14 in
another lab.
Xenograft Model
Athymic nude mice were purchased from National Cancer
Institute (NCI – NCr-nu/nu 01B74). All mice were male,
6–7 weeks old weighing 15–30 grams. Mice were handled
in accord with the approval of the UCDHSC Animal Care
and Use Committee. The groups were defined as: control
chow, LGD1069 (30 mg/kg/day), ROSI (10 mg/kg/day)
and LGD1069/ROSI (30/10 mg/kg/day respectively).
A375(DRO) and M14(5–16) cells were grown in RPMI
media supplemented with 2% FBS and suspended at 5 ×
106 cells/200  μL sterile PBS. Mice were separated into
groups of 8 and after they were anesthetized with an intra-
peritoneal injection of Avertin (0.5–0.7 cc of 32 mg/mL),
5 × 106 tumor cells were injected subcutaneously on the R.
flank of each mouse.
LGD1069, ROSI or the combination was blended into
LabDiet 5001 by TestDiet – a division of Purina Mills, at a
dose estimated to deliver the desired dose based on the
assumption that mice would weigh 20 grams and eat 5
grams of chow/day (based on previous experience). The
LabDiet 5001 alone was used as control chow. Each diet
was irradiated with Cobalt 60 gamma irradiation to steri-
lize the chow for nude mouse consumption. Irradiation of
LGD1069 powder did not affect the ability to inhibit can-
cer cell growth in vitro [8]. Mice were weighed prior to
tumor injection, and food was weighed every two weeks
to estimate the amount of consumption per mouse. Treat-
ment chow was started after tumors reached a volume of
~100–200 mm3.
Tumor Assessment
Mice were observed twice per week and tumors were
measured with electronic calipers. Tumor volume was
estimated using the formula: tumor (length × width ×
height)/0.5236. Based on previous experience and our
animal care facility requirements, the study was designed
to stop when the first group of 8 mice had an average
tumor size of 3000 mm3 for A375(DRO). The M14(5–16)
cell line demonstrated slower growth, thus the tumors
were allowed to grow for 6 weeks. These time points were
chosen to maximize the differences between groups yet
prevent significant morbidity as it had been observed that
mice with tumors at these time points were still mobile,
able to access food and water easily, and had not lost sig-
nificant weight.
Tumor necrosis was assessed by a pathologist blinded to
treatment conditions. The percent of tumor necrosis per
tumor was scored and averaged to allow for statistical
comparison between groups (1-way ANOVA – SigmaS-
tat).Molecular Cancer 2009, 8:16 http://www.molecular-cancer.com/content/8/1/16
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Ligand Resistant Cell Lines
In order to determine the relative importance of RXR and
PPARγ receptors in A375(DRO), we used a novel
approach of developing sub-lines resistant to previously
effective ligands by passaging the cells in media with
slowly increasing drug concentration. We began the titra-
tion with LGD1069, PIO and the combination (1/2 of
each ligand) at the ineffective dose of 10 nM and
increased the concentration every 1–2 weeks until the
cells were growing in the previously inhibitory concentra-
tion of 100 nM. A control population of A375(DRO) were
grown in volume equivalent vehicle (DMSO) as a control
for increasing passage number. The approximate number
weeks for dose titration for all treatment conditions was
14 weeks (+/- 1 week) until cells were growing at a similar
rate in 100 nM of all 3 treatment conditions or volume
equivalent vehicle. Cell identification for these newly
resistant sub-lines is designated by the name of the
exposed ligand followed by "R" for resistant (LGD1069 R;
TZD R; LG/TZD R). The matched cells passed in media
with volume equivalent vehicle are designated DMSO R.
shRNA
We used a lentiviral mediated shRNA system from Sigma
(St. Louis, MO) and followed the manufacturer's proto-
col. Lentiviral particles contain shRNA toward RXRγ or
PPARγ-specific sequences as well as a scrambled (SCR)
sequence that consists of 5 nucleotides that do not match
any known gene transcript in both the murine and human
genome. The infected cells are selected by a puromycin
resistance and then assessed for correct insertion/RNA
inhibition by qRT-PCR or western blot for either RXRγ or
PPARγ. The concentration of puromycin used to select for
DNA construct incorporation cells was 0.4 μg/mL.
Quantitative Reverse transcription-PCR (qRT-PCR)
Total RNA was isolated from A375(DRO) shPPARγ using
the RNeasy Mini Kit (Quiagen, Valencia, CA) as per the
manufacturer's protocol. The mRNA for PPARγ was meas-
ured by real-time Quantitative RT-PCR using ABI PRISM
7700. The sequences of forward and reverse primers as
designed by Primer Express (PE ABI) were 5'-AGT GGA
GAC CGC CCA GGT-3' and 5'-GGG CTT GTA GCA GGT
TGT CTT G-3'.
The TaqMan™ fluorogenic probe used was 6FAM-TGC
TGA ATG TGA AGC CCA TTG AAG ACA-TAMRA.
Amplification reactions, thermal cycling conditions and
generation of a standard curve have been described previ-
ously[8].
Western Blot Analysis
Nuclear extracts were obtained from all four resistant
A375(DRO) sub-lines, A375(DRO) shPPARγ,
A375(DRO) shRXRγ and M14(5–16) shRXRγ for analysis
of RXRα, RXRγ, RARβ (M14(5–16) only) and PPARγ
(A375(DRO) only) proteins utilizing a nuclear extract kit
from Active Motif (catalog #400100, Carlsbad, CA). The
protein content of lysates was measured utilizing a com-
mercial protein assay kit – DC from Bio-Rad (Hercules,
CA). 60 μg of protein was loaded for each sample and the
gel and blot were carried out as previously described [7].
RXRγ (MS-1343-P NeoMarkers) and RXRα (sc D-20) anti-
bodies were used at a concentration of 1:500 and PPARγ
(H-100) rabbit polyclonal ab (sc-7196, Santa Cruz Bio-
technology, Santa Cruz, CA) was used at 1:500. RARβ (sc-
552, Santa Cruz Biotechnology, Santa Cruz, CA) was used
at a dilution of 1:500. After washing, membranes were
incubated for one hour at room temperature with anti-
rabbit IgG conjugated to horse-radish peroxidase at a
1:5000 dilution for RXRs, 1:1000 for PPARγ and 1: 5000
for RARβ (GE Healthcare UK). β-actin or Poly (ADP-
ribose) polymerase (PARP) protein was probed for load-
ing control. The ECL detection reagent from Amersham
Biosciences (Piscataway, NJ) was used for immunodetec-
tion.
Cell growth and proliferation
All four resistant A375(DRO) cell lines, A375(DRO) shP-
PARγ, A375(DRO) shRXRγ and M14(5–16) shRXRγ with
proper SCR control conditions were grown to approxi-
mately 80% confluence in 100 mm tissue culture plates.
Cells were then harvested using Trypsin-EDTA (Invitrogen
Corporation, Carlsbad, CA) and counted using a hemocy-
tometer. Cells were then transferred to a 96-well plate at a
concentration of 500 cells/200 μl of media. Each row of
eight wells received the same cell type and subsequently
the same drug. After cells were allowed to plate down
overnight, media was aspirated and media with the appro-
priate concentration of ligand or equivalent volume of
vehicle was added to each well. Fresh media with vehicle
or ligand was added every 72 hours. At the completion of
6 or 9 days (depending on the experiment), cell prolifera-
tion was assessed following the manufacturers instruc-
tions using the CellTiter 96 Aqueous Non-Radioactive
Cell Proliferation Assay (Promega, Madison, WI). Follow-
ing a two-hour incubation at 37°C, each plate was ana-
lyzed by a MRX Micro plate Reader (Dynatech
Laboratories, Chantilly, VA) using Revelation software.
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